The MTHFR C677T variant causes a change in the shape of the MTHFR enzyme and decreases its ability to bind to FAD.[ref] If you have high homocysteine (a marker for heart disease risk), several studies show that increasing riboflavin lowers homocysteine levels in those with the A/A genotype.[ref][ref] Other research points to riboflavin lowering homocysteine levels only if vitamin B6 levels are adequate.[ref] Bone health : Low riboflavin status in women with MTHFR C677T increases the risk of fractures in osteoporosis.[ref][ref] Related article : Osteoporosis risk factors and genetic variants Heart health: The C677T variant causes a change in the shape of the MTHFR enzyme and decreases its ability to bind to FAD.[ref] If you have high homocysteine (a marker for heart disease risk), several studies show that increasing riboflavin lowers homocysteine levels in those with the A/A genotype.[ref][ref] A 2025 study found that low riboflavin levels combined with the MTHFR C677T homozygous genotype were at an increased risk of hypertension.[ref] Other research indicates that riboflavin lowers homocysteine levels only when vitamin B6 levels are adequate.[ref] Related Articles : MTHFR, Riboflavin, and Blood Pressure | Vitamin B6 Genes Riboflavin affects gene expression: In people with MTHFR C677T (AA genotype, below in genotype report), researchers found that there was higher DNA methylation of NOS3
Both aging and neurodegenerative disorders, such as ALS, share a multifactorial process underlying their progressive evolution, which is genetically determined and epigenetically influenced by the environment
The experimental flowchart is shown in Figure 1
(PubMed) You WC, Brown LM, Zhang L, et al
Retatrutide has not received MHRA or EMA marketing authorisation and is only available within authorised clinical trials
The chemical compound, mechanism of action, and effectiveness are the same because youre taking the same medication
-1775582746855.png&w=3840&q=75)
